The onlinevideoseems to promise everything an arthritis patient could want.
The six-minute segment mimics a morning talk show, using a polished TV host to interview guests around a coffee table. Dr. Adam Pourcho extols the benefits of stem cells and regenerative medicine for healing joints without surgery. Pourcho, a sports medicine specialist, says he has used platelet injections to treat his own knee pain, as well as a tendon injury in his elbow. Extending his arm, he says, Its completely healed.
Brendan Hyland, a gym teacher and track coach, describes withstanding intense heel pain for 18 months before seeing Pourcho. Four months after the injections, he says, he was pain-free and has since gone on a 40-mile hike.
I dont have any pain that stops me from doing anything I want, Hyland says.
Critics suggest the hospitals are exploiting desperate patients and profiting from trendy but unproven treatments.
The videos cheerleading tone mimics theinfomercialsused to promote stem cell clinics, several of which have recently gotten into hot water with federal regulators, saidDr. Paul Knoepfler, a professor of cell biology and human anatomy at the University of California-Davis School of Medicine. But the marketing video wasnt filmed by a little-known operator.
It was sponsored bySwedishMedical Center, the largest nonprofit health provider in the Seattle area.
Swedish is one of a growing number ofrespected hospitalsandhealth systems including theMayo Clinic, theCleveland Clinicand theUniversity of Miami that have entered the lucrative business ofstem cellsandrelated therapies, including platelet injections. Typical treatments involveinjecting patients joints with their own fatorbone marrowcells, or with extracts ofplatelets, the cell fragments known for their role in clotting blood. Many patients seek out regenerative medicine to stave off surgery, even though theevidencesupporting these experimental therapies isthin at best, Knoepfler said.
Hospitals say theyre providing options to patients who have exhausted standard treatments. But critics suggest the hospitals are exploiting desperate patients and profiting from trendybut unproventreatments.
TheFood and Drug Administrationis attempting to shut down clinics that hawk unapproved stem cell therapies, which have been linked toseveral cases of blindnessand atleast 12 serious infections. Although doctors usually need preapproval to treat patients with human cells, the FDA has carved out ahandful of exceptions,as long as the cells meet certain criteria, said Barbara Binzak Blumenfeld, an attorney who specializes in food and drug law at Buchanan Ingersoll & Rooney in Washington.
Hospitals like Mayo are careful to follow these criteria, to avoid running afoul of the FDA, said Dr. Shane Shapiro, program director for the Regenerative Medicine Therapeutics Suites at Mayo Clinics campus in Florida.
While hospital-based stem cell treatments may be legal, theres nostrong evidencethey work, said Leigh Turner, an associate professor at the University of Minnesotas Center for Bioethics who has published a series of articles describing the size and dynamics of thestem cell market.
FDA approval isnt needed and physicians can claim they arent violating federal regulations, Turner said. But just because something is legal doesnt make it ethical.
For doctors and hospitals, stem cells are easy money, Turner said. Patients typically paymore than $700a treatment for platelets and up to$5,000for fat and bone marrow injections. As a bonus, doctors dont have to wrangle with insurance companies, which view the procedures asexperimentaland largelydont cover them.
For doctors and hospitals, stem cells are easy money.
Its an out-of-pocket, cash-on-the-barrel economy, Turner said. Across the country, clinicians at elite medical facilities are lining their pockets by providingexpensive placebos.
Some patient advocates worry that hospitals are more interested in capturing a slice of the stem-cell market than in proving their treatments actually work.
Its lucrative. Its easy to do. All these reputable institutions, they dont want to miss out on the business, said Dr. James Rickert, president of the Society for Patient Centered Orthopedics, which advocates for high-quality care. It preys on peoples desperation.
In a joint statement, Pourcho and Swedish defended the online video.
The terminology was kept simple and with analogies that the lay person would understand, according to the statement. As with any treatment that we provide, we encourage patients to research and consider all potential treatment options before deciding on what is best for them.
But Knoepfler said the guests on the video make several unbelievable claims.
At one point, Dr. Pourcho says thatplatelets release growth factorsthat tell the brain which types of stem cells to send to the site of an injury. According to Pourcho, these instructions make sure that tissues are repaired with the appropriate type of cell, and so you dont get, say, eyeball in your hand.
Knoepfler, who has studied stem cell biology for two decades, said he has never heard of any possibility of growing eyeball or other random tissues in your hand. Knoepfler, who wrote about the video in February on his blog,The Niche, said, Theres no way that the adult brain could send that kind of stem cells anywhere in the body.
The marketing video debuted in July on KING-TV, a Seattle station, as part of a local lifestyles show called New Day Northwest. Although much of the show is produced by the KING 5 news team, some segments like Pourchos interview are sponsored by local advertisers, said Jim Rose, president and general manager of KING 5 Media Group.
After being contacted by KHN, Rose asked Swedish to remove the video from YouTube because it wasnt labeled as sponsored content. Omitting that label could allow the video to be confused with news programming. The video now appears only on the KING-TV website, where Swedish is labeled as the sponsor.
The goal is to clearly inform viewers of paid content so they can distinguish editorial and news content from paid material, Rose said. We value the publics trust.
Federal authorities have recently begun cracking down on doctors who make unproven claims or sell unapproved stem cell products.
In October, theFederal Trade Commissionfined stem cell clinics millions of dollars for deceptive advertising, noting that the companies claimed to be able to treat or cure autism, Parkinsons disease and other serious diseases.
In a recent interview Scott Gottlieb, the FDA commissioner, said the agency will continue to go after what he called bad actors.
Withmore than 700stem cell clinics in operation, the FDA is first targeting those posing the biggest threat, such as doctors who inject stem cells directly into the eye or brain.
There are clearly bad actors who are well over the line and who are creating significant risks for patients, Gottlieb said.
Federal authorities have recently begun cracking down on doctors who make unproven claims or sell unapproved stem cell products.
Gottlieb, set to leave office April 5, said hes also concerned about the financial exploitation of patients in pain.
Theres economic harm here, where products are being promoted that arent providing any proven benefits and where patients are paying out-of-pocket, Gottlieb said.
Dr. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, said there is a broad spectrum of stem cell providers, ranging from university scientists leading rigorous clinical trials to doctors who promise stem cells are for just about anything. Hospitals operate somewhere in the middle, Marks said.
The good news is that theyre somewhat closer to the most rigorous academics, he said.
The Mayo Clinics regenerative medicine program, for example, focuses conditions such asarthritis, where injections pose few serious risks, even if thats not yet the standard of care, Shapiro said.
Rickert said its easy to see why hospitals are eager to get in the game.
The market for arthritis treatment is huge and growing. At least30 million Americanshave the most common form of arthritis, with diagnoses expected to soar as the population ages. Platelet injections for arthritis generatedmore than $93 millionin revenue in 2015, according to an article last year in The Journal of Knee Surgery.
We have patients in our offices demanding these treatments, Shapiro said. If they dont get them from us, they will get them somewhere else.
Doctors at the Mayo Clinic try to provide stem cell treatments and similar therapies responsibly, Shapiro said. Ina paper published this year,Shapiro described the hospitals consultation service, in which doctors explain patients options and clear up misconceptions about what stem cells and other injections can do. Doctors can refer patients to treatment or clinical trials.
Most of the patients do not get a regenerative [stem cell] procedure, Shapiro said. They dont get it because after we have a frank conversation, they decide, Maybe its not for me.
Although some hospitals boast of high success rates for their stem cell procedures,published researchoften paints a different story.
TheMayo Clinic websitesays that 40 to 70% of patients find some level of pain relief. Atlanta-basedEmory Healthcareclaims that 75 to 80% of patients have had significant pain relief and improved function. In the Swedish video, Pourcho claims we can treat really any tendon or any joint with PRP.
The strongest evidence for PRP is in pain relief for arthritic knees and tennis elbow, where it appears to be safe and perhaps helpful, said Dr. Nicolas Piuzzi, an orthopedic surgeon at the Cleveland Clinic.
But PRP hasnt been proven to help every part of the body, he said.
PRP has been linked to serious complications when injected to treatpatellar tendinitis,an injury to the tendon connecting the kneecap to the shinbone. In a 2013 paper, researchers described the cases of three patients whose pain got dramatically worse after PRP injections. One patient lost bone and underwent surgery to repair the damage.
People will say, If you inject PRP, you will return to sports faster, said Dr. Freddie Fu, chairman of orthopedic surgery at the University of Pittsburgh Medical Center. But that hasnt been proven.
A2017 studyof PRP found it relieved knee pain slightly better than injections of hyaluronic acid. But thats nothing to brag about, Rickert said, given thathyaluronic acid therapy doesnt work, either. While some PRP studies have shown morepositive results, Rickert notes that most were so small orpoorly designedthat theirresults arent reliable.
In its 2013 guidelines for knee arthritis, theAmerican Academy of Orthopaedic Surgeonssaid it is unable to recommend for or against PRP.
PRP is sort of a buyer beware situation, said Dr. William Li, president and CEO of the Angiogenesis Foundation, whose research focuses on blood vessel formation. Its the poor mans approach to biotechnology.
Tests of other stem cell injections also have failed to live up to expectations.
Shapiro published a rigorously designed study last year inCartilage, a medical journal, that found bone marrow injections were no better at relieving knee pain than saltwater injections. Rickert noted that patients who are in pain often get relief from placebos. The more invasive the procedure, the stronger the placebo effect, he said, perhaps because patients become invested in the idea that an intervention will really help. Even saltwater injections help 70% of patients, Fu said.
A 2016 review in theJournal of Bone and JointSurgery concluded that the value and effective use of cell therapy in orthopaedics remain unclear. The following year, a review in theBritish Journal of Sports Medicineconcluded, We do not recommend stem cell therapy for knee arthritis.
Shapiro said hospitals and health plans are right to be cautious.
Many patients have trouble sorting through the hype.
The insurance companies dont pay for fat grafting or bone-marrow aspiration, and rightly so, Shapiro said. Thats because we dont have enough evidence.
Rickert, an orthopedist in Bedford, Ind., said fat, bone marrow and platelet injections should be offered only through clinical trials, which carefully evaluate experimental treatments. Patients shouldnt be charged for these services until theyve been tested and shown to work.
Orthopedists surgeons who specialize in bones and muscles have a history of performing unproven procedures, includingspinal fusion, surgery forrotator cuff diseaseandarthroscopyfor worn-out knees, Turner said. Recently, studies have shown them to be no more effective than placebos.
Some argue that joint injections shouldnt be marketed as stem cell treatments at all.
Piuzzi said he prefers to call the injections orthobiologics,noting that platelets are not even cells, let alone stem cells. The number of stem cells in fat and bone marrow injections is extremely small, he said. In fat tissue, only about 1 in 2,000 cells is a stem cell, according to a March paper inThe Bone & Joint Journal. Stem cells are even rarer in bone marrow, where 1 in 10,000 to 20,000 cells is a stem cell.
Patients are attracted to regenerative medicine because they assume it will regrow their lost cartilage, Piuzzi said. Theres no solid evidence that the commercial injections used today spur tissue growth, Piuzzi said. Although doctors hope that platelets will release anti-inflammatory substances, which could theoretically help calm an inflamed joint, they dont know why some patients who receive platelet injections feel better, but others dont.
So, it comes as no surprise that many patients have trouble sorting through the hype.
Florida resident Kathy Walsh, 61, said she wasted nearly $10,000 on stem cell and platelet injections at a Miami clinic, hoping to avoid knee replacement surgery.
When Walsh heard about a doctor in Miami claiming to regenerate knee cartilage with stem cells, it seemed like an answer to a prayer, said Walsh, of Stuart, Fla. Youre so much in pain and so frustrated that you cling to every bit of hope you can get, even if it does cost you a lot of money.
The injections eased her pain for only a few months. Eventually, she had both knees replaced. She has been nearly pain-free ever since. My only regret, she said, is that I wasted so much time and money.
KaiserHealthNewsis an editorially independent program of the Henry J.KaiserFamily Foundation, a nonprofit, nonpartisanhealthpolicy research and communication organization not affiliated withKaiserPermanente. You can view the original report on itswebsite.
- Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast - FierceBiotech - November 22nd, 2020
- Benefits of Hematopoietic Stem Cell Transplantation in Advanced Myelodysplastic Syndromes - Hematology Advisor - November 22nd, 2020
- YOUR HEALTH: Your body may already have the answer to knee pain - WQAD.com - November 22nd, 2020
- Providing CAR T-Cell Therapy for Patients With DLBCL During COVID-19 - Targeted Oncology - November 22nd, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization - OrthoSpineNews - November 22nd, 2020
- Stem Cell Therapy Market 2020 Trends, Market Share, Industry Size, Growth, Sales, Opportunities, Analysis and Forecast To 2026 - The Daily... - November 22nd, 2020
- Animal Stem Cell Therapy Market 2020 Impact of COVID-19 | Size, Share & Latest Trends, Analysis Report by Manufacturers, Application, Type and... - November 22nd, 2020
- Canine Stem Cell Therapy Market 2020 impact of COVID-19 on Industry Size, Share, Global Analysis, Development Status, Regional Trends, Opportunity... - November 22nd, 2020
- Stem Cell Therapy Market, Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast up to 2026 - The Daily Philadelphian - November 22nd, 2020
- gift of life marrow registry announces new center for cell and gene therapy - The Boca Raton Tribune - November 22nd, 2020
- Global Canine Stem Cell Therapy Industry Market Analysis, Key Company Profiles, Types, Applications and Forecast To 2026 - Royal Sutton News - November 22nd, 2020
- Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis? - DocWire News - November 22nd, 2020
- Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord in patients with Acute Myeloid Leukemia (AML) -... - November 22nd, 2020
- Impact Analysis of Covid-19 On Global Stem Cell Therapy Market Continues to Expand to Support Development and Top Players: Magellan, Medipost Co.,... - November 22nd, 2020
- Adrenoleukodystrophy Treatment Market: Rising awareness about rare diseases to drive the market - BioSpace - November 22nd, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - The Baytown Sun - November 16th, 2020
- Mesenchymal stem cells in the treatment of COVID-19-progress and challenges - DocWire News - November 16th, 2020
- The Animal Stem Cell Therapy market to fill the growth bill in the next decade - The Think Curiouser - November 16th, 2020
- Malaysia Animal Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2027 - Eurowire - November 16th, 2020
- Addenbrooke's becomes first regional centre to offer CAR-T cell treatment for cancer patients - Cambridge Network - November 16th, 2020
- Stem Cell Therapy Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - The Daily Philadelphian - November 16th, 2020
- Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review - DocWire News - November 16th, 2020
- Global cryotherapy market size to reach USD 6.72 billion by 2026 - GlobeNewswire - November 16th, 2020
- Stem Cell Therapy Market 2020 Future Growth Factors and Opportunities by 2025 - PRnews Leader - November 16th, 2020
- Stem Cell Therapy Market 2020 Trends, Growth Insight, Share, Competitive Analysis, Statistics, Regional and Global Industry Forecast To 2025 - PRnews... - November 16th, 2020
- BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for... - November 16th, 2020
- Stem Cell Banking Market To See Massive Growth By 2027| Cryo-Save AG, StemCyte India Therapeutics, SMART CELLS PLUS, Vita 34, LifeCell - PRnews Leader - November 9th, 2020
- It's time for Kentucky to talk to expectant parents about benefits of cord blood banking - Courier Journal - November 9th, 2020
- Global Stem Cell Therapy Market 2020 : Analysis of Expansion Strategy on Industry, Growth Factors and Expected CAGR Of Top Leaders, Upcoming... - November 9th, 2020
- Stem Cell Banking Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2028|Esperite, Caladrius Biosciences, Via Cord, CBR... - November 9th, 2020
- Doctors Consider Convalescent T Cell Therapy for COVID-19 - The Scientist - November 7th, 2020
- Canine Stem Cell Therapy Market Analysis, Latest Trends and Regional Growth Forecast by Types and Applications 2020 - TechnoWeekly - November 7th, 2020
- Cancer Stem Cell Therapy Market: Industry Trends and Developments 2020-2025 - Zenit News - November 7th, 2020
- Stem Cell Therapy Market 2020: Size, Professional Survey, and Forecast to 2025 - PRnews Leader - November 7th, 2020
- The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser - November 7th, 2020
- Novel Targeted Drugs are Changing the Treatment of Diffuse Large B-Cell Lymphoma - Curetoday.com - November 7th, 2020
- Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease - GlobeNewswire - November 7th, 2020
- Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American... - November 7th, 2020
- bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition -... - November 7th, 2020
- Voters approve stem cell research bonds, but other health care measures defeated - State of Reform - State of Reform - November 5th, 2020
- Stem cells key to ALS therapy - Agoura Hills Acorn - November 5th, 2020
- Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. - UroToday - November 5th, 2020
- New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation - DocWire News - November 5th, 2020
- Emerging Trends in Global Canine Stem Cell Therapy Market Report 2020,Deeply Analyzes Share, Types, Applications and Future Demands by Key Players-... - November 5th, 2020
- Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL - OncLive - November 5th, 2020
- Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 - PRnews Leader - November 5th, 2020
- Stem Cell Therapy Market Insights Global Analysis and Forecast by (2020 2027) - The Think Curiouser - November 5th, 2020
- Animal Stem Cell Therapy Consumption Market To Observe Exponential Growth By 2020-2027 | Verified Market Research - Eurowire - November 5th, 2020
- Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case - FiercePharma - November 5th, 2020
- Stem Cell Therapy Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of... - November 5th, 2020
- Animal Stem Cell Therapy Market Future Demand Analysis with Forecast 2020 to 2027 - PRnews Leader - November 5th, 2020
- Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX... - November 5th, 2020
- Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of... - November 5th, 2020
- CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology... - November 5th, 2020
- Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting - Business Wire - November 5th, 2020
- XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma - BioSpace - November 5th, 2020
- Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |... - November 5th, 2020
- Animal Stem Cell Therapy Market Size 2020-2026 Review, Key Findings, Growth Strategy, Developing Technologies, Trends And Global Forecast By Regions -... - November 5th, 2020
- Covid-19 Impact On Animal Stem Cell Therapy Market Analysis, Trends, Share, Size, Consumption 2020 2026 | MediVet Biologic, VETSTEM BIOPHARMA, J-ARM,... - November 5th, 2020
- Stem Cell Therapy for Autism: Effects & Costs in 2020 - November 1st, 2020
- aHSCT Gets a Boost in US With NMSS Recommendations - Multiple Sclerosis News Today - November 1st, 2020
- Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View - November 1st, 2020
- How pain changes your brain - News - The University of Sydney - November 1st, 2020
- Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? - SurvivorNet - October 31st, 2020
- Stem Cell and Regenerative Therapy Market Monitoring Growth Opportunities 2024 - Aerospace Journal - October 31st, 2020
- Animal Stem Cell Therapy Market 2020 Size, Share, Trends Analysis Report by Application, Region (North America, South America, Asia, and Europe) and... - October 31st, 2020
- Canine Stem Cell Therapy Market: Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2026 - PRnews Leader - October 31st, 2020
- What Are the Treatment Options When Lymphoma Returns? - SurvivorNet - October 31st, 2020
- Philadelphia Based Company Wants to Bring Back the Dead With Stem Cells - Gilmore Health News - October 31st, 2020
- Next Steps: What to Do When the First Non-Hodgkin Lymphoma Treatment You Try Doesnt Work - SurvivorNet - October 31st, 2020
- Stem Cell Therapy Market | Growth Strategies Adopted By Top Key Players,Future Trends ,Application Worldwide And Assessment To 2026 - PRnews Leader - October 31st, 2020
- Here's What Happens When Lab-Grown Mini-Lungs Are Exposed to SARS-CoV-2 - ScienceAlert - October 31st, 2020
- Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant... - October 31st, 2020
- Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader - October 31st, 2020
- Innovations in the Rheumatoid Arthritis Stem Cell Therapy Field Likely to Aid the Growth of the Rheumatoid Arthritis Stem Cell Therapy Market 2018 to... - October 31st, 2020
- Stem Cell Umbilical Cord Blood Market to Enable the Stakeholders to Capitalize on the Prevailing Industry Opportunities with Investment Analysis By... - October 31st, 2020
- Cynata looking to revolutionise stem cell therapy - The West Australian - October 28th, 2020
- Exclusive: "Ending Disease" Documentary Explores How Stem Cell Therapy Aims to Cure the Incurable - Prevention.com - October 28th, 2020
- Stem Cell Therapy Industry Market Size, Global Analytical Overview, Key Players, Regional Demand, Trends and Forecast To 2026 - Aerospace Journal - October 28th, 2020
- Study: Poverty Linked to Higher Risk of Death Among Children with Cancer Undergoing Stem Cell Transplantation - PRNewswire - October 28th, 2020